KMDS
E-submission
Search
- Page Path
- HOME > Search
Original Article
- Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson’s Disease
- Cameron Dietiker, Soeun Kim, Yunxi Zhang, Chadwick W. Christine
- J Mov Disord. 2019;12(2):91-96. Published online May 30, 2019
- DOI: https://doi.org/10.14802/jmd.18049
- 9,846 View
- 175 Download
- 10 Web of Science
- 11 Crossref
-
Abstract
PDF - Objective
In Parkinson’s disease (PD), vitamin B12 levels are lower, and comorbid B12 deficiency has been associated with the development of neuropathy and early gait instability. Because little is known about B12 supplement use in PD, we sought to evaluate its use in a large PD cohort and, as an exploratory analysis, to determine whether baseline characteristics or disease progression differed according to B12 supplementation.
Methods
We utilized data collected as part of the National Institutes of Health Exploratory Trials in PD (NET-PD) Long-term Study (LS-1), a longitudinal study of 1,741 participants. We stratified subjects into 4 groups according to daily supplement use: no B12, multivitamin (MVI) containing < 100 μg B12, B12 ≥ 100 μg, and MVI + B12 ≥ 100 μg. Clinical outcomes were assessed at 3 years for each group using the Unified Parkinson’s Disease Rating Scale (UPDRS), its subscores, and selected individual questions.
Results
Of the 1,147 participants who completed the 3-year visit, 41% took an MVI, 2% took B12, 3% took MVI + B12, and 54% reported taking no supplements. At 3 years, no significant differences in clinical outcomes were observed. However, there was a trend toward lower hazard ratios for developing sensory symptoms (UPDRS Item 17) in the MVI (p = 0.08) and B12 + MVI (p = 0.08) groups compared to that in the no supplement group.
Conclusion
These results show that supplementation with vitamin B12 ≥ 100 μg is uncommon in early PD. The finding of a trend toward a lower hazard ratio for the development of sensory symptoms in those taking an MVI or B12 + MVI warrants further study. -
Citations
Citations to this article as recorded by
- Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials
Chadwick W. Christine, Peggy Auinger, Esther A.R. Forti, Lyvin Tat, Noemi Cannizzaro, Arshi Mustafa, Jay M. Iyer, David Oakes, Ralph Green
Journal of Parkinson’s Disease.2024; 14(6): 1243. CrossRef - Peripheral neuropathy in Parkinson’s disease: prevalence and functional impact on gait and balance
Marta Francisca Corrà, Nuno Vila-Chã, Ana Sardoeira, Clint Hansen, Ana Paula Sousa, Inês Reis, Firmina Sambayeta, Joana Damásio, Margarida Calejo, Andreas Schicketmueller, Inês Laranjinha, Paula Salgado, Ricardo Taipa, Rui Magalhães, Manuel Correia, Walte
Brain.2023; 146(1): 225. CrossRef - Could Vitamins Have a Positive Impact on the Treatment of Parkinson’s Disease?
Sandeep, Manas Sahu, Linchi Rani, Arun Kharat, Amal Mondal
Brain Sciences.2023; 13(2): 272. CrossRef - Long‐Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men
Mario H. Flores‐Torres, Chadwick W. Christine, Kjetil Bjornevik, Samantha A. Molsberry, Albert Y. Hung, Brian C. Healy, Deborah Blacker, Michael A. Schwarzschild, Alberto Ascherio
Movement Disorders.2023; 38(5): 866. CrossRef - Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
Mubasher A. Qamar, Silvia Rota, Lucia Batzu, Indu Subramanian, Cristian Falup-Pecurariu, Nataliya Titova, Vinod Metta, Iulia Murasan, Per Odin, Chandrasekhara Padmakumar, Prashanth L. Kukkle, Rupam Borgohain, Rukmini Mridula Kandadai, Vinay Goyal, Kallol
Frontiers in Neurology.2023;[Epub] CrossRef - An Investigation into the Effects of Water- and Fat-Soluble Vitamins in Alzheimer's and Parkinson's Diseases
Mohammad Shahverdi, Zahra Sourani, Marzieh Sargolzaie, Mostafa Modarres Mousavi, Behnam Bakhtiari moghadam, Sadegh Shirian
The Neuroscience Journal of Shefaye Khatam.2023; 11(3): 95. CrossRef - Folic Acid and Vitamin B12 Prevent Deleterious Effects of Rotenone on Object Novelty Recognition Memory and Kynu Expression in an Animal Model of Parkinson’s Disease
Gabriela Canalli Kretzschmar, Adriano D. S. Targa, Sheila Coelho Soares-Lima, Priscila Ianzen dos Santos, Lais S. Rodrigues, Daniel A. Macedo, Luis Felipe Ribeiro Pinto, Marcelo M. S. Lima, Angelica Beate Winter Boldt
Genes.2022; 13(12): 2397. CrossRef - The Role of Vitamins in Neurodegenerative Disease: An Update
Sachchida Nand Rai, Payal Singh, Harry W.M. Steinbusch, Emanuel Vamanu, Ghulam Ashraf, Mohan Prasad Singh
Biomedicines.2021; 9(10): 1284. CrossRef - Vitamin B12 measurements across neurodegenerative disorders
Nijee S. Luthra, Ariane H. Marcus, Nancy K. Hills, Chadwick W. Christine
Journal of Clinical Movement Disorders.2020;[Epub] CrossRef - Lower Vitamin B12 Level at Multiple System Atrophy Diagnosis Is Associated With Shorter Survival
Stuart J. McCarter, Elizabeth A. Coon, Rodolfo Savica, Erik K. St Louis, James H. Bower, Eduardo E. Benarroch, Paola Sandroni, Phillip Low, Wolfgang Singer
Movement Disorders.2020; 35(8): 1462. CrossRef - Protection from the Pathogenesis of Neurodegenerative Disorders, including Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Huntington’s Disease, and Parkinson’s Diseases, through the Mitigation of Reactive Oxygen Species
S* Madireddy, S Madireddy
Journal of Neuroscience and Neurological Disorders.2019; 3(2): 148. CrossRef
- Relationships of B12 and Homocysteine with Outcomes in the SURE-PD, SURE-PD3, and STEADY-PDIII Trials
First
Prev
